IL270326B2 - Tdr with new preparations, combinations and their methods - Google Patents

Tdr with new preparations, combinations and their methods

Info

Publication number
IL270326B2
IL270326B2 IL270326A IL27032619A IL270326B2 IL 270326 B2 IL270326 B2 IL 270326B2 IL 270326 A IL270326 A IL 270326A IL 27032619 A IL27032619 A IL 27032619A IL 270326 B2 IL270326 B2 IL 270326B2
Authority
IL
Israel
Prior art keywords
compound
hydrogen
deramciclane
propan
phenoxy
Prior art date
Application number
IL270326A
Other languages
English (en)
Hebrew (he)
Other versions
IL270326B (en
IL270326A (enrdf_load_stackoverflow
Original Assignee
Exciva GmbH
Sreenivasarao Vepachedu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2017/048748 external-priority patent/WO2018039642A1/en
Publication of IL270326A publication Critical patent/IL270326A/en
Application filed by Exciva GmbH, Sreenivasarao Vepachedu filed Critical Exciva GmbH
Publication of IL270326B publication Critical patent/IL270326B/en
Publication of IL270326B2 publication Critical patent/IL270326B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL270326A 2017-05-04 2019-10-31 Tdr with new preparations, combinations and their methods IL270326B2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762501696P 2017-05-04 2017-05-04
PCT/US2017/048748 WO2018039642A1 (en) 2016-08-26 2017-08-25 Compositions and methods thereof
TW106129169A TW201815387A (zh) 2016-08-26 2017-08-28 組成物及其方法
US201862634162P 2018-02-22 2018-02-22
US201862635554P 2018-02-27 2018-02-27
US201862636099P 2018-02-27 2018-02-27
US201862636171P 2018-02-28 2018-02-28
PCT/US2018/030978 WO2018204713A1 (en) 2017-05-04 2018-05-03 Targeted drug rescue with novel compositions, combinations, and methods thereof

Publications (3)

Publication Number Publication Date
IL270326A IL270326A (enrdf_load_stackoverflow) 2018-05-03
IL270326B IL270326B (en) 2022-10-01
IL270326B2 true IL270326B2 (en) 2023-02-01

Family

ID=65431106

Family Applications (1)

Application Number Title Priority Date Filing Date
IL270326A IL270326B2 (en) 2017-05-04 2019-10-31 Tdr with new preparations, combinations and their methods

Country Status (13)

Country Link
EP (1) EP3618819A4 (enrdf_load_stackoverflow)
JP (2) JP7514078B2 (enrdf_load_stackoverflow)
KR (2) KR102444803B1 (enrdf_load_stackoverflow)
CN (1) CN110831584B (enrdf_load_stackoverflow)
AU (2) AU2018261654A1 (enrdf_load_stackoverflow)
BR (1) BR112019022902A2 (enrdf_load_stackoverflow)
CA (2) CA3062452C (enrdf_load_stackoverflow)
IL (1) IL270326B2 (enrdf_load_stackoverflow)
MA (1) MA49464A (enrdf_load_stackoverflow)
RU (1) RU2760558C9 (enrdf_load_stackoverflow)
TW (1) TWI787260B (enrdf_load_stackoverflow)
WO (1) WO2018204713A1 (enrdf_load_stackoverflow)
ZA (1) ZA201908006B (enrdf_load_stackoverflow)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204713A1 (en) * 2017-05-04 2018-11-08 Exciva Ug (Haftungsbeschränkt) Targeted drug rescue with novel compositions, combinations, and methods thereof
BR112021018564A2 (pt) * 2019-03-18 2021-11-30 Avanir Pharmaceuticals Inc Métodos de tratamento de sintomas negativos de esquizofrenia usando dextrometorfano deuterado e quinidina
JP7400818B2 (ja) * 2019-06-06 2023-12-19 Jsr株式会社 感放射線性樹脂組成物、レジストパターン形成方法及び化合物
CA3177454A1 (en) 2020-05-19 2021-11-25 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
CN116473077B (zh) * 2023-05-08 2025-04-11 广东方中高新材料有限公司 一种n,n配位的镓配合物抗菌剂的合成和应用
CN116473073A (zh) * 2023-05-08 2023-07-25 广东方中高新材料有限公司 一种含镓配合物的吡唑醚菌酯增效悬浮制剂及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004006930A1 (en) * 2002-07-17 2004-01-22 Avanir Pharmaceuticals Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
WO2014011590A2 (en) * 2012-07-12 2014-01-16 Javitt Daniel C Composition and method for treatment of depression and psychosis in humans

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241065A (en) * 1979-07-02 1980-12-23 E. I. Du Pont De Nemours And Company Fluoro analogs of hydrocodone and oxycodone useful as analgesics, narcotic antagonists or both
US4950658A (en) * 1988-12-06 1990-08-21 Board Of Trustees Of Southern Illinois Univ. Method of medical treatment of Alzheimer's disease
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US6207674B1 (en) * 1999-12-22 2001-03-27 Richard A. Smith Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
US6335371B1 (en) * 2000-11-28 2002-01-01 Orion Corporation Method for inducing cognition enhancement
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
KR20080097443A (ko) 2006-02-03 2008-11-05 아바니르 파마슈티컬스 덱스트로메토판 및 퀴니딘을 포함하는, 우울, 불안 및 신경퇴행성 장애 치료용 약제학적 조성물
NZ582124A (en) * 2007-05-21 2012-07-27 Reviva Pharmaceuticals Inc Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
US8017623B2 (en) * 2008-07-03 2011-09-13 Trinity Laboratories, Inc. Dextromethorphan hydrochloride
CA2903757A1 (en) * 2013-03-07 2014-09-12 Mindlab LLC Pain medicine combination and uses thereof
JP2016516202A (ja) * 2013-03-15 2016-06-02 キネメッド， インコーポレイテッド バイオマーカー
EP3708168A3 (en) * 2014-09-14 2020-12-09 Avanir Pharmaceuticals, Inc. Combinations of deuterated dextromethorphan and quinidine for the treatment of agitation in dementia
RU2764716C2 (ru) * 2016-08-26 2022-01-19 Экссива Уг (Хафтунгзбешрэнкт) Композиции и связанные с ними способы
WO2018204713A1 (en) * 2017-05-04 2018-11-08 Exciva Ug (Haftungsbeschränkt) Targeted drug rescue with novel compositions, combinations, and methods thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004006930A1 (en) * 2002-07-17 2004-01-22 Avanir Pharmaceuticals Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
WO2014011590A2 (en) * 2012-07-12 2014-01-16 Javitt Daniel C Composition and method for treatment of depression and psychosis in humans

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DOO-YEOUN CHO ET AL:, SELECTIVE INHIBITION OF CYTOCHROME P450 2D6 BY SARPOGRELATE AND ITS ACTIVE METABOLITE, M-L, IN HUMAN LIVER MICROSOMES, 28 October 2013 (2013-10-28) *
KYUNG BAE ET AL:, APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING IN PREDICTING DRUG-DRUG INTERACTIONS FOR SARPOGRELATE HYDROCHLORIDE IN HUMANS, 1 September 2016 (2016-09-01) *
MEI JUAN XU ET AL:, EFFECT OF SARPOGRELATE HYDROCHLORIDE ON CYTOCHROME P450 2D1/2 IN RATS, 1 January 2014 (2014-01-01) *

Also Published As

Publication number Publication date
JP7514078B2 (ja) 2024-07-10
IL270326B (en) 2022-10-01
ZA201908006B (en) 2021-04-28
EP3618819A1 (en) 2020-03-11
CA3062452C (en) 2023-10-24
CA3138116A1 (en) 2018-11-08
JP2020518617A (ja) 2020-06-25
IL270326A (enrdf_load_stackoverflow) 2018-05-03
KR20200062078A (ko) 2020-06-03
CN110831584B (zh) 2023-03-10
CA3062452A1 (en) 2018-11-08
AU2018261654A1 (en) 2019-11-14
RU2019137004A3 (enrdf_load_stackoverflow) 2021-06-04
RU2019137004A (ru) 2021-06-04
RU2760558C2 (ru) 2021-11-29
RU2760558C9 (ru) 2022-02-22
AU2021215274B2 (en) 2022-11-03
JP2023143940A (ja) 2023-10-06
MA49464A (fr) 2020-04-29
BR112019022902A2 (pt) 2020-05-19
TW201842902A (zh) 2018-12-16
CN110831584A (zh) 2020-02-21
KR20210130827A (ko) 2021-11-01
WO2018204713A1 (en) 2018-11-08
EP3618819A4 (en) 2021-01-20
TWI787260B (zh) 2022-12-21
AU2021215274A1 (en) 2021-09-02
KR102444803B1 (ko) 2022-09-19

Similar Documents

Publication Publication Date Title
US20210228508A1 (en) Compositions and methods thereof
AU2021215274B2 (en) Targeted drug rescue with novel compositions, combinations, and methods thereof
US20200261442A1 (en) Targeted drug rescue with novel compositions, combinations, and methods thereof
CA3221280A1 (en) Enantiomeric entactogen compositions and methods of their use
CA3179785A1 (en) Advantageous benzofuran compositions for mental disorders or enhancement
US20200069674A1 (en) Targeted drug rescue with novel compositions, combinations, and methods thereof
JP2024508545A (ja) セロトニン作動性薬に関係する障害の治療に有用なセロトニン作動性薬としてのインドール誘導体
WO1996031470A1 (en) Novel heterocyclic compounds
US20220296586A1 (en) Novel compositions, combinations, and methods thereof
WO1996031479A1 (en) Novel heterocyclic compounds